Back to search

France· FR:69456091

ALLERGIFLASH 0,05 %, collyre en solution en récipient unidose

A medicinal product containing chlorhydrate de lévocabastine, registered in France by LABORATOIRE CHAUVIN.

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedALLERGIFLASH 0,05 %, collyre en solut…ATC—REGISTER NO.FR:69456091PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CHLORHYDRATE DE LÉVOCABASTINE
Manufacturer
LABORATOIRE CHAUVIN
Country
France (FR)
ATC code
—
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400934691638
    10 récipient(s) unidose(s) polyéthylène basse densité (PEBD) suremballée(s)/surpochée(s) de 0,3 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Chlorhydrate de lévocabastine in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All chlorhydrate de lévocabastine products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Levocamed, Livostin
  • Belgium · Livostin, Nasasinuspray Anti-Allergie
  • Czechia · Livostin
  • Germany · Levocabastin, Levocamed
  • Denmark · Benaliv
  • Spain · Bilina, Reactine
  • Finland · Livostin
  • Greece · Livostin
  • Iceland · Livostin
  • Italy · Levoreact, Levoreact Oftalmico
  • Luxembourg · Livostin, Nasasinuspray Anti-Allergie
  • Netherlands · Livocab
  • Norway · Livostin
  • Sweden · Livostin
  • Slovakia · Livostin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bfa24adb-5c65-4593-86d1-82c299d73912
GET /v1/drugs/bfa24adb-5c65-4593-86d1-82c299d73912?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69456091",
  "date_amm": "2010-01-22",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "CHLORHYDRATE DE LÉVOCABASTINE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "collyre en solution",
  "voies_administration": "ophtalmique",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about chlorhydrate de lévocabastine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.